Literature DB >> 24889167

Hepatocellular carcinoma and other hepatic malignancies: MR imaging.

Christopher G Roth1, Donald G Mitchell2.   

Abstract

Magnetic resonance (MR) imaging surpasses all other imaging modalities in characterizing liver lesions by virtue of the exquisite tissue contrast, specificity for various tissue types, and extreme sensitivity to contrast enhancement. In addition to differentiating benign from malignant lesions, MR imaging generally discriminates between the various malignant liver lesions. Hepatocellular carcinoma constitutes most primary malignant liver lesions and usually arises in the setting of cirrhosis. Intrahepatic cholangiocarcinoma is a distant second and features distinctly different imaging features. Overall, metastases are the most common malignant liver lesions and arise from several primary neoplasms; most commonly gastrointestinal, lung, breast, and genitourinary.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cholangiocarcinoma; Embryonal sarcoma; Epithelioid hemangioendothelioma; Fibrolamellar carcinoma; Hepatic lymphoma; Hepatoblastoma; Hepatocellular carcinoma; Liver metastases

Mesh:

Substances:

Year:  2014        PMID: 24889167     DOI: 10.1016/j.rcl.2014.02.015

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  10 in total

Review 1.  Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.

Authors:  Anum Aslam; Amita Kamath; Bradley Spieler; Mark Maschiocchi; Carl F Sabottke; Victoria Chernyak; Sara C Lewis
Journal:  Abdom Radiol (NY)       Date:  2021-04-15

Review 2.  Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma.

Authors:  Myeong-Jin Kim; Sunyoung Lee; Chansik An
Journal:  Eur Radiol       Date:  2019-02-20       Impact factor: 5.315

3.  Effect of Perioperative Comprehensive Nursing Intervention on Transcatheter Arterial Chemoembolization in Patients with Primary Hepatic Carcinoma.

Authors:  Min Hu; Ziyan Fan; Yu Han
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

4.  Contributions of Magnetic Resonance Imaging to Gastroenterological Practice: MRIs for GIs.

Authors:  Christopher G Roth; Dina Halegoua-De Marzio; Flavius F Guglielmo
Journal:  Dig Dis Sci       Date:  2018-05       Impact factor: 3.199

Review 5.  Focal liver lesions: Practical magnetic resonance imaging approach.

Authors:  António P Matos; Fernanda Velloni; Miguel Ramalho; Mamdoh AlObaidy; Aruna Rajapaksha; Richard C Semelka
Journal:  World J Hepatol       Date:  2015-08-08

6.  HYPERVASCULAR LIVER LESIONS IN RADIOLOGICALLY NORMAL LIVER.

Authors:  Enio Campos Amico; José Roberto Alves; Dyego Leandro Bezerra de Souza; Fellipe Alexandre Macena Salviano; Samir Assi João; Adriano de Araújo Lima Liguori
Journal:  Arq Bras Cir Dig       Date:  2017 Jan-Mar

Review 7.  Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 2.

Authors:  Miguel Ramalho; António P Matos; Mamdoh AlObaidy; Fernanda Velloni; Ersan Altun; Richard C Semelka
Journal:  Radiol Bras       Date:  2017 Mar-Apr

Review 8.  Application of Different Imaging Methods in the Early Diagnosis of Primary Hepatic Carcinoma.

Authors:  Xin'ai Wu; Jianbo Li; Cheng Wang; Guojian Zhang; Na Zheng; Xuemei Wang
Journal:  Gastroenterol Res Pract       Date:  2015-12-24       Impact factor: 2.260

9.  Liver involvement by multiple myeloma presenting as hypervascular focal lesions in a patient with chronic hepatitis B infection.

Authors:  Magda Marcon; Lorenzo Cereser; Rossano Girometti; Palmina Cataldi; Stefano Volpetti; Massimo Bazzocchi
Journal:  BJR Case Rep       Date:  2016-05-08

Review 10.  Hepatic Hemangioendothelioma: An update.

Authors:  Mayur Virarkar; Mohammed Saleh; Radwan Diab; Melissa Taggart; Peeyush Bhargava; Priya Bhosale
Journal:  World J Gastrointest Oncol       Date:  2020-03-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.